BIO SOURCING

Bio-Sourcing has developed a BioMilk platform, a new paradigm-shifting technology to produce biosimilar molecules in the milk of genetically engineered goats. This breakthrough development producing genetically modified goats using CRISPR-Cas9 produces 100% pure progeny of goats with genes of interest of biosimilar. Our bioproduction method is up to 5x more cost-efficient reducing costs from €100-200 of to €25 per gram of API and has 10x less CAPEX reducing investment costs from €200-300 million to 35 million and 1000x lower Co2 footprint reducing it from 25T to 5 per Kg of API, compared to conventional methods, allowing its scalability and industrialization with significantly less carbon footprint. The BioMilk platform has the potential to be market creating and disrupt the biotherapeutics manufacturing and biosimilar markets with an enormous market opportunity of €100B. The main goal of the project is to successfully complete the non-clinical analytical studies for three biosimilars with the highest market potential and perform the phase-I clinical validation of the first biosimilar. This will help Bio-Sourcing to close a licensing deal for the sales of the biosimilars to a pharma or biogeneric-producing company by 2027. Bio-Sourcing will remain the exclusive producer and act as a supplier of API to its customers who will sell fully formulated biosimilars. Bio-Sourcing is expected to receive upfront payments and milestones (€40M in total per biosimilar) and generate longer-term revenue through sales of API and royalty payment on net sales (5%). Bio-Sourcing seeks EICA blended finance (€2.5M grant and €10M equity), which will enable Bio-Sourcing to reach its value inflection point of successfully completing the important Phase I study for the first biosimilar from the BioMilk platform for human health application.